Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience
暂无分享,去创建一个
G. Garcia-Manero | T. Kadia | F. Ravandi | C. Dinardo | S. Garcés | N. Short | Z. Dreyer | A. Stevens | J. Brackett | Michael Roth | M. Redell | C. Nunez | N. Daver | D. McCall | Laurie Toepfer | A. Bidikian | G. Issa | M. Konopleva | G. Montalban Bravo | Amber Gibson | Adriana Trabal | Joanna S. Yi | Hana Paek | Branko Cuglievan | Jia He | Andrea N Marcogliese | Miriam Garcia | Meredith Buzbee | Naval G Daver
[1] S. Tasian,et al. Relapsed pediatric acute myeloid leukaemia: state-of-the-art in 2023 , 2023, Haematologica.
[2] M. Konopleva,et al. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML , 2022, Blood advances.
[3] B. Ebert,et al. Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. , 2022, Blood.
[4] L. Smit,et al. Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies , 2022, Cancers.
[5] M. Konopleva,et al. Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma , 2021, Cancers.
[6] G. Marcucci,et al. Outcomes of Venetoclax and Hypomethylating Agents (HMA) in Adult Patients with KMT2A-Rearranged Leukemias , 2021, Blood.
[7] M. Konopleva,et al. Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience , 2021, Blood advances.
[8] Tongtong Sun,et al. Low‐dose decitabine plus venetoclax is safe and effective as post‐transplant maintenance therapy for high‐risk acute myeloid leukemia and myelodysplastic syndrome , 2021, Cancer science.
[9] S. Raimondi,et al. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531 , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Alonzo,et al. Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG , 2021, Cancers.
[11] J. Tuscano,et al. Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center , 2021, Frontiers in Oncology.
[12] T. Seth,et al. Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country , 2021, Leukemia & lymphoma.
[13] M. Konopleva,et al. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3‐ITD and IDH mutations , 2020, Cancer.
[14] J. Welch,et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. , 2020, The Lancet. Haematology.
[15] A. Tefferi,et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients , 2020, American journal of hematology.
[16] A. Letai,et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.
[17] Amanda C. Winters,et al. Single‐center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia , 2020, Pediatric blood & cancer.
[18] M. Konopleva,et al. Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. , 2020, Blood advances.
[19] J. Novak,et al. Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial. , 2020, Blood.
[20] C. Pui,et al. Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. , 2020, The Lancet. Oncology.
[21] T. Duong,et al. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience. , 2020, Leukemia research.
[22] Qi Zhang,et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. , 2020, Blood.
[23] K. Ross,et al. A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. , 2019, Cancer cell.
[24] M. Konopleva,et al. Venetoclax-based therapies for acute myeloid leukemia. , 2019, Best practice & research. Clinical haematology.
[25] A. Letai,et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. , 2019, Blood.
[26] M. Konopleva,et al. Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies , 2018, American journal of hematology.
[27] J. Jorgensen,et al. How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia? , 2017, Clinics in laboratory medicine.
[28] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[29] G. Leverger,et al. Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] C. Zwaan,et al. Pediatric AML: From Biology to Clinical Management , 2015, Journal of clinical medicine.
[31] S. Raimondi,et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] G. Leverger,et al. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] L. Lam,et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.
[34] C. Pui,et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M. Loh,et al. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A therapeutic advances in childhood leukemia (TACL) consortium study , 2010, Pediatric blood & cancer.
[36] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.